Cargando…
Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292542/ http://dx.doi.org/10.1186/2051-1426-2-S3-P249 |
| _version_ | 1782352497773379584 |
|---|---|
| author | Hilton, Traci Sanborn, Rachel Boulmay, Brian Li, Rui Spieler, Bradley Happel, Kyle Paustian, Christopher Moudgil, Tarsem Dubay, Christopher Fisher, Brenda Mederos, Eileen Ochoa, Augusto Urba, Walter J Hu, Hong-Ming Fox, Bernard |
| author_facet | Hilton, Traci Sanborn, Rachel Boulmay, Brian Li, Rui Spieler, Bradley Happel, Kyle Paustian, Christopher Moudgil, Tarsem Dubay, Christopher Fisher, Brenda Mederos, Eileen Ochoa, Augusto Urba, Walter J Hu, Hong-Ming Fox, Bernard |
| author_sort | Hilton, Traci |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4292542 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42925422015-01-15 Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC Hilton, Traci Sanborn, Rachel Boulmay, Brian Li, Rui Spieler, Bradley Happel, Kyle Paustian, Christopher Moudgil, Tarsem Dubay, Christopher Fisher, Brenda Mederos, Eileen Ochoa, Augusto Urba, Walter J Hu, Hong-Ming Fox, Bernard J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4292542/ http://dx.doi.org/10.1186/2051-1426-2-S3-P249 Text en Copyright © 2014 Hilton et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Hilton, Traci Sanborn, Rachel Boulmay, Brian Li, Rui Spieler, Bradley Happel, Kyle Paustian, Christopher Moudgil, Tarsem Dubay, Christopher Fisher, Brenda Mederos, Eileen Ochoa, Augusto Urba, Walter J Hu, Hong-Ming Fox, Bernard Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC |
| title | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC |
| title_full | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC |
| title_fullStr | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC |
| title_full_unstemmed | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC |
| title_short | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC |
| title_sort | preliminary analysis of immune responses in patients enrolled in a phase ii trial of cyclophosphamide with allogenic dribble vaccine alone (dpv-001) or with gm-csf or imiquimod for adjuvant treatment of stage iiia or iiib nsclc |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292542/ http://dx.doi.org/10.1186/2051-1426-2-S3-P249 |
| work_keys_str_mv | AT hiltontraci preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT sanbornrachel preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT boulmaybrian preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT lirui preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT spielerbradley preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT happelkyle preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT paustianchristopher preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT moudgiltarsem preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT dubaychristopher preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT fisherbrenda preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT mederoseileen preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT ochoaaugusto preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT urbawalterj preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT huhongming preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc AT foxbernard preliminaryanalysisofimmuneresponsesinpatientsenrolledinaphaseiitrialofcyclophosphamidewithallogenicdribblevaccinealonedpv001orwithgmcsforimiquimodforadjuvanttreatmentofstageiiiaoriiibnsclc |